

# Index

- Abacavir, 142–143
- Abscess
- central venous catheter-related, 98
  - periosteal, 55
- Acidosis, malaria-related, 127, 129–130
- Acyclovir, as encephalitis treatment, 177, 179–181
- Adefovir dipivoxil, as hepatitis B treatment, 85, 86
- Adenoviruses, as encephalitis cause, 178
- Adrenaline, as malaria treatment, 128
- Amoxicillin, 6, 94
- use in neonatal intensive care units, 99–100
- Amoxicillin resistance, in *Hemophilus influenzae*, 41, 42–44
- Amphotericin B, 240–241. *See also* Deoxycholate amphotericin B
- Ampicillin, as neonatal sepsis treatment, 99
- Ampicillin resistance, in *Escherichia coli*, 235
- Anemia
- aplastic, 111, 112
  - autoimmune hemolytic, 114
  - Fanconi's, 114
  - malaria-related, 126, 127, 130–132
  - sickle cell, 48, 54
- Energy, 64
- Anidulafungin, 243
- Antenatal care, for syphilis prevention, 37
- Antibiotic resistance. *See also* specific antibiotics
- in neonates, 99–100, 101
- Antibiotics. *See also* specific antibiotics
- broad spectrum, 93
- Anti-inflammatory therapy, for sepsis, 66–67
- Antiretroviral therapy
- for human immunodeficiency virus infection, 141–144, 146
  - during pregnancy, 149–153
- Arboviruses, 189
- Arthritis, septic
- diagnosis and management of, 52–53
  - etiological agents of, 48
  - major clinical manifestations of, 50, 51
- Aspergillosis, invasive, 237–247
- treatment of, 237–245
- Ataxia telangiectasia, 112, 113
- Augmentin, 216
- Auto-immunization, 146
- Azithromycin
- as acute otitis media treatment, 42, 43
  - as chronic recurrent multifocal osteomyelitis treatment, 59
  - as *Mycoplasma pneumoniae*-related encephalopathy treatment, 182
  - as syphilis treatment, 39
- Aztreonam, 7
- Bacteria. *See also* specific bacteria
- antibiotic-resistant, as bone and joint infection cause, 48
- Bacterial infections. *See also* specific bacteria
- as malaria complication, 128
  - neonatal, 97–101
  - primary immune deficiency-associated, 112
- B cells, 110
- memory, 20–21
  - in sepsis, 64
- Bisphosphonates, 59
- Bone and joint infections, 47–62. *See also* Osteomyelitis
- diagnosis and management of, 52–59
  - epidemiology of, 47–48
  - major clinical manifestations of, 50–52
  - microbiology and pathogenesis of, 48–50
  - misdiagnosis of, 52
- Bordetella pertussis*, as pertussis cause, 105
- Borrelia burgdorferi*, as bone and joint infection cause, 48
- Breast-feeding, as human immunodeficiency virus infection transmission method, 149, 153
- Brucella*, as bone and joint infection cause, 48
- Burkholderi* infections, 112
- Candida*
- gastrointestinal overgrowth of, 15
  - as invasive infection cause, 237
- Candidemia
- central venous catheter-related, 98
  - neonatal, 101
- Candidiasis
- azole antifungal therapy for, 239
  - chronic mucocutaneous, 112–113
  - neonatal, 101

- Candidiasis *contd.*  
 in neutropenic patients, 245  
 primary immune deficiency-related, 112–113
- Capnocytophaga canimorsus*, as sepsis cause, 63
- Carbapenems, 7, 120
- Cartilage hair hypoplasia, 115
- Caspofungin, 242, 243–244
- Catheterization, central venous, as neonatal sepsis cause, 98
- CD4+ T cell count, in human immunodeficiency virus infection, 137–140, 142, 143, 146
- CD4+ T cells, in sepsis, 64
- CD40 ligand deficiency, 113, 115
- Cefdinir, 6
- Cefepime, 99
- Cefotaxime, 6, 7, 94, 99
- Cefotaxime resistance, 99–100
- Cefpodoxime, 7
- Ceftazidime, 7
- Ceftriaxone, 6
- Cefuroxime, 6
- Cefuroxime axetil, 6
- Celiac disease, 17
- Center for Disease Prevention and Control, syphilis eradication program of, 36
- Central lines, as neonatal sepsis cause, 98
- Cephalosporins, 54, 99, 100, 120, 216  
 extended-spectrum, bacterial resistance to, 7
- Cesarean sections, in human immunodeficiency virus-positive women, 150
- CHARGE syndrome, 115
- Chediak–Higashi syndrome, 111, 113, 114
- Chlamydial infections, prenatal screening for, 38
- Chloramphenicol, as *Mycoplasma pneumoniae*-related encephalopathy treatment, 182
- Chloroquine, *Plasmodium falciparum* resistance to, 126–127
- Cholangitis, sclerosing, 113
- Cholera vaccines, 73–76
- Choline binding protein, 19, 20
- Chronic granulomatous disease, 112, 113, 115, 116, 117, 237
- Cilistatin, 7
- Citrobacter*, antibiotic-resistant, 7
- Clarithromycin, as *Ureaplasma urealyticum* treatment, 99
- Clindamycin  
 as methicillin-resistant *Staphylococcus aureus* infection treatment, 5–6  
 as *Mycoplasma hominis* infection treatment, 99  
 as streptococcal group A infection treatment, 186–187  
 as toxic shock syndrome treatment, 194
- Clostridium difficile*, gastrointestinal overgrowth of, 15
- Common variable immunodeficiency, 112, 113
- Connective tissue disorders, primary immune deficiency-related, 115
- Corticosteroids, as sepsis treatment, 66
- C-reactive protein, 54, 56, 97, 99
- Cystic fibrosis, 113
- Cytomegalovirus infection, 112, 155–159  
 congenital, 155–159  
 therapeutic interventions for, 157–159  
 maternal, 155–157  
 primary *versus* recurrent infection, 155–156
- Delivery, in human immunodeficiency virus-positive women, 150  
 with premature labor, 151–152
- Dendritic cells  
 follicular, in mucosal vaccine development, 20–21  
 maturation of, 18–20  
 in sepsis, 64
- Dengue, 178
- Dengue vaccines, 3
- Deoxycholate amphotericin B (DAMB)  
 as invasive aspergillosis treatment, 237–238, 240, 241–242, 243, 244  
 as neonatal fungal infection treatment, 101
- Dermatitis  
 atopic, 192  
 eczemoid, 113, 114
- Dermatological disorders, primary immune deficiency-related, 113, 116
- Desferrioxamine, 128
- Dexamethasone, 128
- Diarrhea  
 cholera vaccine-related, 74  
 chronic granulomatous disease-related, 113  
 enterotoxigenic *Escherichia coli*-related, 75–76, 77  
 Shiga-toxin producing *Escherichia coli*-related, 76, 77  
 traveler's, 77  
 weanling, in infants, 77
- Dichloroacetate, 128
- Di George syndrome, 114–115
- Diphtheria toxoid, 222
- Diplococcus intracellularis*, 203
- Discitis  
 diagnosis and management of, 57  
 major clinical manifestations of, 51
- Diseases, new, 4
- Dog bite wounds, 63
- Dopamine, as malaria treatment, 128
- Doxycycline  
 as *Mycoplasma hominis* infection treatment, 99  
 as *Ureaplasma urealyticum* treatment, 99
- Dysgammaglobulinemia, 112, 116

- “Eagle effect,” 187
- Echinocandins, 242, 243
- Encephalitis, 177–183
  - differentiated from encephalopathy, 178–179
  - epidemiology of, 177–178
  - herpes simplex, 177, 179–181
  - Japanese, 178
  - Mycoplasma pneumoniae*-related, 178, 181–182
  - non-polio enteroviruses-related, 181
  - West Nile, 178
- Encephalopathy, differentiated from encephalitis, 178–179
- Endocarditis, central venous catheter-related, 98
- Enterocavair, as hepatitis B treatment, 86
- Enteric diseases, prevention of, 71–82
- Enterobacter*, antibiotic-resistant, 7
- Enterobacter cloacae*, cefotaxime-resistant, 100
- Enterococcus faecium*, vancomycin-resistant, 6
- Enteroviruses
  - as encephalitis cause, 178
  - non-polio, as encephalitis cause, 181
- Enterovirus infections, 112
- Epidemics
  - ancient, 4
  - of meningococcal disease, 202–203
- Epstein–Barr virus infections, 112, 192
- Escherichia coli*
  - ampicillin-resistant, 235
  - as bone and joint infection cause, 48
  - enterotoxigenic, vaccines against, 74, 77–79
  - extended-spectrum  $\beta$ -lactamase production in, 7, 99
  - as febrile neutropenia cause, 120
  - as neonatal infection cause, 98
  - as neonatal sepsis cause, 93
  - O157:H7 serotype, 76
  - Shiga-toxin producing (enterohemorrhagic), 76–77
- Escherichia coli* heat-labile enterotoxin, 20
- Famciclovir, as hepatitis B treatment, 86
- Fasciitis, necrotizing, 185, 186, 187
- Flucloxacillin
  - as toxic shock syndrome treatment, 194
  - use in neonatal intensive care units, 99–100
- Fluconazole
  - as invasive aspergillosis treatment, 239, 241, 244
  - as neonatal candidemia treatment, 101
- Flucytosine, 101, 237
- Fluoroquinolones, as *Mycoplasma pneumoniae*-related encephalopathy treatment, 182
- Fluxcoloxacillin, 54
- Fungal infections. *See also* Aspergillosis; Candidiasis; Chlamydial infections
  - neonatal, 95, 98, 101
  - Fungal infections *contd.*
    - in neutropenic patients, 244–245
    - primary immune deficiency-associated, 112–113
- Ganciclovir, 157–158
- Gastrointestinal disorders, primary immune deficiency-related, 113
- Gastrostomy, 144
- Gatifloxacin, 6–7
- Gentamicin, 54, 93, 99
- Gonorrhea, prenatal screening for, 38
- Gram-negative bacteria
  - antibiotic-resistant, 7
  - cefotaxime-resistant, 99–100
  - as febrile neutropenia cause, 120
  - as neonatal infection cause, 98
- Gram-positive bacteria, as febrile neutropenia cause, 120
- Granulocyte colony-stimulating factor, 244–245
- Granulocyte-macrophage colony-stimulating factor, 244–245
- Griselli syndrome, 111, 113
- GW1263, 159
- Haemophilus influenzae*. *See Hemophilus influenzae*
- Hand-foot-mouth disease, 181
- Hearing loss, cytomegalovirus infection-related, 156–158
- Hemophilus*, as bone and joint infection cause, 48
- Hemophilus influenzae*
  - amoxicillin-resistant, 41, 42–44
  - mucosal binding to, 15
  - as otitis media cause, 41
  - as sepsis cause, 63
- Hemophilus influenzae* type b, 15
  - in immunocompromised patients, 112
  - vaccines against, 221–229
    - formulation of, 222–224
    - herd immunity effect of, 212
    - nasopharyngeal carriage of, 225–226
- Hemophilus influenzae* conjugate vaccine, 48
- Heparin, as malaria treatment, 128
- Hepatitis, viral, 83–90
- Hepatitis B, 89
  - management of, 84–86
  - perinatal transmission of, 83–84
- Hepatitis B e antigen (HBeAG), 83
- Hepatitis B surface antigen (HBsAG), 83
  - prenatal screening for, 38
- Hepatitis B vaccination, 84
- Hepatitis C, 83, 84, 86–88, 89
  - management of, 87–88
  - transmission of, 87
- Herpes simplex virus, as encephalitis cause, 177, 179–181

- Hippocrates, 202
- Human immunodeficiency virus (HIV) infection, 135–147, 138  
 CD4+ count in, 137–140, 142, 143, 146  
 clinical and immunological classification of, 136–138  
 diagnosis of, 141  
 epidemiology of, 135  
 management of  
   with antiretroviral therapy, 141–144  
   future approaches in, 145–146  
   multidisciplinary, 140–141  
 mucosal immunity against, 18  
 perinatal transmission of, prevention of, 149–154  
*Pneumocystis carinii* infection associated with, 113  
 prenatal screening for, 38  
 risk of progression of, 138–140  
 transition from pediatric to adult care in, 144–145
- Hyper IgE syndrome, 112  
 X-linked, 113
- Hyperimmune serum, 128
- Hypogammaglobulinemia, 114
- Hypovolemia, in acidosis of severe malaria, 130
- Imidazoles, 237, 239
- Imipenem, 7, 93
- Immune response, in sepsis, 63–65
- Immune system, 110
- Immunity  
 acquired, 110  
 herd, meningococcal vaccine-related, 27–28  
 innate, 110  
 mucosal, 13–22  
   immunoglobulins in, 16–18  
   vaccine-induced, 13–15
- Immunocompromised patients. *See also* Human immunodeficiency virus (HIV) infection; Primary immune deficiency (PID)  
 aspergillosis in, 237  
 treatment of, 240–245
- Immunodeficiency centromeric instability dysmorphism, 114
- Immunoglobulin A  
 mucosal, 13  
 secretory, in mucosal secretions, 16–18
- Immunoglobulin A1 proteases, 13
- Immunoglobulin G, in mucosal secretions, 16, 17
- Immunological memory, 224–225
- Immunological priming, 224–225
- Immunosuppressive therapy, as aspergillosis risk factor, 237
- Immunotherapy  
 adjuvant, for aspergillosis, 244–245  
 for human immunodeficiency virus infection, 146
- Infections. *See also* Bacterial infections; Fungal infections; Sepsis; Viral infections  
 neonatal, 91–96  
   antibiotic therapy for, 91–95  
   indications for treatment of, 91–92  
   lumbar puncture in, 92–93
- Infectious mononucleosis, 192
- Inflammatory bowel disease, 17
- Influenza virus, as encephalitis cause, 178
- Insulin, as sepsis treatment, 66
- Interferon  
 as hepatitis B treatment, 85  
 as hepatitis C treatment, 87–88
- Interferon- $\gamma$ , as fungal infection treatment, 245
- Interleukin-2, as human immunodeficiency virus infection treatment, 146
- Interleukin-6, as neonatal sepsis marker, 97
- Interleukin-8, as neonatal sepsis marker, 97, 99
- Interleukin-10, as neonatal sepsis marker, 97
- Intravenous immunoglobulin  
 as necrotizing fasciitis treatment, 187  
 as streptococcal toxic shock syndrome treatment, 186  
 as toxic shock syndrome treatment, 194
- Itraconazole, 239, 240–241, 242
- Job syndrome, 237
- Joint infections. *See* Bone and joint infections
- Kawasaki disease, 194–197  
 similarity with toxic shock syndrome, 195  
 superantigens in, 195–198
- Ketoconazole, 239
- Kingella kingae*  
 as bone and joint infection cause, 48  
 as discitis cause, 57
- Klebsiella*  
 extended-spectrum  $\beta$ -lactamase production in, 7, 99  
 as febrile neutropenia cause, 120
- Kussmaul's breathing, 129
- $\beta$ -Lactam antibiotics  
 as febrile neutropenia treatment, 120  
 hypersensitivity to, 6  
 as streptococcal group A infection treatment, 186–187
- $\beta$ -Lactamase inhibitors, 120
- $\beta$ -Lactamases, 41, 42  
 extended spectrum, 7, 99
- Lamivudine  
 as hepatitis B treatment, 85–86  
 as human immunodeficiency virus infection treatment, 142–143  
 in pregnant women, 151

- Leukemia, febrile neutropenia associated with, 119–121
- Linezolid, 6
- Lipopolysaccharide, 63
- Liver transplantation, as hepatitis B treatment, 86
- Low birth weight, congenital syphilis-related, 36–37
- Lumbar puncture
- for encephalitis diagnosis, 179
  - for neonatal sepsis diagnosis, 92–93
- Lymphocytes, 110
- Lymphoma, 112, 116
- Lymphopenia, 111
- Lymphoproliferative disease, X-linked, 116
- Macrophages, 110
- Magnetic resonance imaging (MRI)
- for osteomyelitis evaluation, 55
  - for septic arthritis evaluation, 52
- Major histocompatibility complex
- in acquired immunity, 110
  - in sepsis, 64–65
- Malaria, 125–134
- cerebral, 127, 128–129
  - epidemiology of, under stable transmission, 125–126
  - general supportive care in, 128
  - management of complications of, 128–132
  - severe, 127–128
- Mannose-binding lectin, 121–123
- Measles, as encephalitis cause, 178, 182
- Measles, mumps, rubella vaccine, 182
- Meningitis, 117, 201
- candidal, 101
  - central venous catheter-related, 98
  - Gram-negative, treatment of, 99
  - history of, 202–203
  - host response to, 203–204
  - lipopolysaccharide in, 63
  - neonatal, 92, 95
- Meningococcal vaccines, 26–27, 204–207
- serogroup B meningococcal, 205–206, 207
- Meningococcus*, 15, 23–33, 112
- carriage of, 24–25
  - as commensal organism, 23
  - diversity of, 25–26
  - transmission of, 23–24
  - vaccines against, 26–27
- Meropenem, 7, 93
- as Gram-negative meningitis treatment, 99
- Methicillin resistance, in *Staphylococcus aureus*, 5–6, 47, 54
- Micafungin, 243–244
- Molluscum contagiosum, 112
- Moraxella catarrhalis*, as otitis media cause, 41
- Mosquitoes
- as arbovirus vectors, 178
  - as malaria vectors, 125
- Mucosal secretions. *See also* Immunity, mucosal immunoglobulins in, 16–18
- Mumps, as encephalitis cause, 178, 182
- Mycobacterium tuberculosis*, as bone and joint infection cause, 48
- Mycoplasma hominis*, as neonatal infection cause, 99
- Mycoplasma pneumoniae*, as encephalitis cause, 178, 181–182
- Myelodysplasia, 111
- Nafcillin, as coagulase-negative staphylococci infection treatment, 99
- National Institute of Child Health and Human Development Neonatal Research Network Centers, 97–98
- Neisseria*, as bone and joint infection cause, 48
- Neisseria lactamica*, 15, 26
- carriage of, 24
- Neisseria meningitidis*, 23, 203
- carriage of, 24
  - genetic diversity of, 25–26
  - genetic polymorphisms of, 203–204
  - mucosal binding to, 15
  - as sepsis cause, 63
  - serogroups of, 201–202, 205–207
- Neonatal intensive care units, antimicrobial utilization practices in, 99–101
- Neonates, infections in, 91–96. *See also* specific infections
- antibiotic therapy for, 91–95
  - bacterial infections, 97–101
  - fungal infections, 98, 101
  - indications for treatment of, 91–92
  - lumbar puncture for evaluation of, 92–93
- Neurological disorders, primary immune deficiency-related, 114
- Neutropenia, 111
- chemotherapy-related, as aspergillosis risk factor, 237, 244–245
  - cyclical, 113
  - febrile, 119–124
  - infection susceptibility in, 121–123
  - treatment of, 120–121
- Nevirapine, 143–144, 151
- Nijmegen breakage syndrome, 114
- Nipah paramyxovirus, 178
- Non-nucleoside reverse transcriptase inhibitors, 142
- Nonsteroidal anti-inflammatory drugs
- as chronic recurrent multifocal osteomyelitis treatment, 59
  - as superantigen-mediated disease risk factor, 192–193

- Nuclear factor  $\kappa$ B, 63, 68
- Nucleoside analogues, as neonatal mitochondrial encephalopathy cause, 152–153
- Nucleoside reverse transcriptase inhibitors, 142
- Nucleotide reverse transcriptase inhibitors, 142
- Nystatin, 237
- Omenn's syndrome, 115
- O157 antigen, immunity to, 77
- Osteomyelitis
- acute hematogenous, 50, 51
  - diagnosis and management of, 53–56
  - central venous catheter-related, 98
  - chronic
    - diagnosis and management of, 57–58, 59
    - recurrent multifocal, 58–59
  - chronic relapsing multifocal, 51
  - etiological agents of, 48–50
  - major clinical manifestations of, 50, 51, 52
  - microbiology and pathogenesis of, 48–50
  - proximal femoral, 53
  - puncture wound, 51, 58
  - Salmonella*, sickle cell anemia-related, 48
  - subacute, 50, 51
    - diagnosis and management of, 56–57
    - “tennis shoe,” 58
    - wound-associated, 48
- Otitis media, 188
- antibiotic therapy for, 41–45
  - effect of bacterial antibiotic resistance on, 41–44
  - recurrent/difficult to treat, 6–7
  - Streptococcus pneumoniae*-related, 211, 215, 217
- Oxacillin
- as coagulase-negative staphylococci infection treatment, 99
  - as late-onset sepsis treatment, 93
  - as vancomycin substitute, 100
- Parainfluenza vaccines, 3
- Pediatric Prevention Network (PPN), 100
- Penicillin
- as neonatal infection treatment, 94
  - as pneumococcal infection treatment, 6
  - pneumococcal isolates' resistance to, 7
  - as streptococcal group A infection treatment, 186–187
  - as streptococcal pharyngitis treatment, 188
  - as syphilis treatment, 35
  - as toxic shock syndrome treatment, 194
- Penicillin resistance, in *Streptococcus pneumoniae*, 42
- Pentoxifylline, 128
- Periosteum, osteomyelitis of, 49, 50
- Pertussis, resurgence of, 106–107
- Pertussis vaccines, 105–108
- Peyer's patches, 13
- Phagocytic disorders, 112
- Pharyngitis, group a streptococcus-related, 188–189
- Plasminogen activator inhibitor type 1 4G/5G promoter polymorphism, 67–68
- Plasmodium falciparum*, as malaria cause, 125, 126
- antimalarial drug resistance in, 126–127
- Pleconaril, 181
- Pneumatoceles, staphylococcal, 113, 114
- Pneumococcal infections. *See also Streptococcus pneumoniae*
- antibiotic treatment of, 6–7
- Pneumococcal vaccines, 19, 20
- conjugate
- effect on nasal pneumococcal colonization rates, 15–16
  - effect on *Streptococcus pneumoniae* carriage resistance, 211–219
  - effect on *Streptococcus pneumoniae* nasopharyngeal carriage, 212, 214–217
  - 7-valent, 7
- Pneumococci, respiratory epithelial cell adhesion by, 17
- Pneumococcus*, 15
- Pneumocystis carinii* pneumonia, 113, 136
- Pneumolysin, 19
- Pneumonia
- Pneumocystis carinii*, 113, 136
  - Streptococcus pneumoniae*-related, 211
- Poliomyelitis, 14
- Polio vaccines, mucosal immune response to, 14–15
- Polymerase chain reaction (PCR)
- for encephalitis diagnosis, 177, 179, 182
  - for neonatal sepsis diagnosis, 97
- Posaconazole, 239, 241
- Pregnancy
- antiretroviral therapy during, 149–153
  - in untreated syphilis, 35–37
- Premature birth
- antiretroviral therapy as risk factor for, 151–152
  - congenital syphilis-related, 36–37
- Prenatal screening, 37, 38
- Primaquine, as malaria treatment, 125
- Primary immune deficiency (PID), 109–117
- diagnosis of, 110–116
- Procalcitonin, as neonatal sepsis marker, 97
- Protease inhibitors, 142
- Protein C, as sepsis treatment, 65, 68
- Pseudomonas aeruginosa*
- as bone and joint infection cause, 48
  - as osteomyelitis cause, 58
- Pseudoparalysis, 50
- Psoriasis, 192
- Purine nucleotide phosphorylase deficiency, 114

- Quinine, 128  
 Quinolones, 58, 120  
 Quinsy, 188  
 Quinupristin/dalfopristin, 6
- Radius bone, chronic osteomyelitis of, 49  
 Ravuconazole, 239, 241  
 Respiratory disorders, primary immune deficiency-related, 113  
 Respiratory distress, malaria-related, 127, 129  
 Respiratory distress syndrome, neonatal, 92  
 Respiratory syncytial virus infections, 112  
 Retinopathy, cerebral malaria-related, 129  
 Rheumatic fever, 188  
 Rheumatoid arthritis, 115  
 Ribavirin, as hepatitis C treatment, 87, 88  
 Rubella  
   as encephalitis cause, 178, 182  
   prenatal screening for, 38  
 Rupture of membranes, in human immunodeficiency virus-positive women, 151–152
- Salmonella*, as bone and joint infection cause, 48  
*Salmonella landau*, O157 antigen expression in, 77  
 Schwachmann-Diamond syndrome, 115  
 Seizures, malaria-related, 128–129  
 Sepsis, 63–70  
   childhood cancer-related, 121  
   coagulase-negative staphylococcal, 93, 95  
   meningococcal  
     genetic marker for, 67–68  
     models of, 64–65  
     pathogenesis of, 63–65  
     role of genetic polymorphisms in, 67, 68  
     susceptibility to, 67  
     treatment of, 65–67, 68  
   neonatal, diagnosis of, 97  
   osteomyelitis-related, 51  
   pathogenesis of, 63–64  
   septic arthritis-related, 51  
 Septicemia, bone and joint infections-related, 50  
*Serratia*, antibiotic-resistant, 7  
 Severe combined immune deficiency (SCID), 109, 111, 112–113, 115, 116  
 Sex trade workers, syphilis treatment and prophylaxis in, 38–39  
 Sexually-transmitted diseases, control strategies for, 38  
 Shiga toxin, *Escherichia coli*-produced, 76–77  
*Shigella* vaccines, 71–73, 78  
 Shigellosis, 71  
 Shock, septic, 63  
 Sickle cell anemia/disease, 54  
   *Salmonella* osteomyelitis associated with, 48  
 Single nucleotide polymorphism (SNP), 67
- Skeletal disorders, primary immune deficiency-related, 115  
 Staphylococci, coagulase-negative  
   flucloxacillin-resistant, 93  
   as neonatal infection/sepsis cause, 93, 97, 99, 100–101  
*Staphylococcus aureus*  
   as bone and joint infection cause, 48–50  
   as discitis cause, 57  
   as febrile neutropenia cause, 120  
   methicillin-resistant, 5–6, 47, 54  
   as neonatal infection cause, 95, 98  
   as neonatal sepsis cause, 93  
   as sepsis cause, 63  
   virulence factors of, 191  
 Stillbirth, congenital syphilis-related, 36, 37–39  
 Streptococci,  $\alpha$ -hemolytic, as bone and joint infection cause, 48  
 Streptococci group A, virulence factors of, 191  
 Streptococci group A infections, 185–190  
   antibiotic prophylaxis against, 187–188  
   bone and joint infections, 48  
   contacts with cases of, 187–188  
   invasive, 185–188  
   pharyngitis, 188–189  
   sepsis, 63  
   treatment of, 185–190  
 Streptococci group B, superantigens of, 191  
 Streptococci group B infections  
   bone and joint infections, 48  
   neonatal sepsis, 97–98, 231–236  
     adverse effects of, 232–233  
     infection control-based prevention of, 233  
     intrapartum antibiotic prevention of, 233–235, 236  
     postpartum antibiotic prevention of, 235  
     treatment *versus* prevention of, 233  
     vaccination-based prevention of, 235–236  
   sepsis, 63  
 Streptococci group C, superantigens of, 191  
 Streptococci group G  
   as bone and joint infection cause, 48  
   superantigens of, 191  
*Streptococcus agalactiae*, 231  
*Streptococcus pneumoniae*  
   antibiotic-resistant, 6–7, 211–212  
   conjugate pneumococcal vaccine-related prevention of, 211–219  
   penicillin resistance, 42, 54  
   pediatric colonization rate of, 211  
*Streptococcus pneumoniae* infections  
   otitis media, 41–42  
   primary immune deficiency-associated, 112  
   sepsis, 63  
 Sulfadoxine-pyrimethamine, 126

- Superantigens, 191–193  
 as Kawasaki disease cause, 195–198  
 in toxic shock syndrome, 193–194
- Syphilis  
 congenital, 35–40  
 epidemiology of, 35–37  
 failure to prevent, 37–38  
 mass treatment strategies for, 38–39  
 treatment of, 35  
 maternal, 35–37  
 untreated, 37–38  
 treatment of, 39
- Systemic lupus erythematosus, 115, 116
- T-cell receptor repertoire studies  
 of Kawasaki disease, 195–196  
 of toxic shock syndrome, 193, 196
- T cells, 110
- Telithromycin, 7
- Tetanus toxoid, 222
- Tick-borne viruses, as encephalitis cause, 178
- Tobramycin, 94  
 use in neonatal intensive care units, 99–100
- Toll-like receptors, 19, 63
- Toxic shock-like syndrome, 191, 192
- Toxic shock syndrome, 191, 192  
 adjunctive treatment of, 194  
 similarity with Kawasaki disease, 195  
 staphylococcal, 192  
 streptococcal  
 intravenous immunoglobulin treatment of, 186  
 mortality rate in, 185–186  
 superantigens in, 193–194
- Toxic shock syndrome toxin, 193
- Triazoles, 239, 241–243
- Trimethoprim-sulfamethoxazole, 5, 6, 42  
 bacterial resistance to, 6
- Tuberculosis  
 differentiated from acute osteomyelitis, 50  
 osteoarticular, 59
- Tumor necrosis factor- $\alpha$ , plasminogen activator inhibitor type 1 4G/5G promoter polymorphism-inducing activity of, 67–68
- Tumor necrosis factor antagonists, as sepsis treatment, 66
- Tympanocentesis, double, 41
- Ultrasound, for osteomyelitis evaluation, 55
- Ureaplasma urealyticum* infections, neonatal, 99
- Ureidopenicillins, 120
- Vaccines, 1–4  
 cholera, 73–76  
 dengue, 3
- Vaccines *contd.*  
 developments in, 1–3  
 enterogenic *Escherichia coli*, 74, 77–79  
*Hemophilus influenzae* type b, 221–229  
 formulation of, 222–224  
 nasopharyngeal carriage of, 225–226  
*Hemophilus influenzae* conjugate, 48  
 hepatitis B, 84  
 herd immunity and, 13–15  
 history of, 1  
 human immunodeficiency virus infection, 146  
 meningococcal, 26–27, 204–207  
 serogroup B meningococcal, 205–206, 207  
 mucosal, 13–22  
 dendritic cells in, 18–20  
*Escherichia coli* heat-labile enterotoxin adjuvant for, 20  
 follicular dendritic cells and, 20–21  
 herd immunity and, 13–15  
 parainfluenza, 3  
 pertussis, 105–108  
 Shiga-toxin producing *Escherichia coli*, 76–77  
*Shigella*, 71–73  
 streptococcal conjugate, 235–236
- Valaciclovir, as encephalitis treatment, 180–181
- Vancomycin, 5, 6  
 use in neonatal intensive care units, 100–101
- Vancomycin resistance, in *Enterococcus faecium*, 6
- Varicella, 112
- Vectors, 3
- Very-low-birth-weight infants  
 fungal infections in, 101  
 group B streptococcal infection in, 97–98
- Vibrio cholerae*, as cholera cause, 73–74
- Viral infections. *See also* specific viruses  
 mucosal immunity against, 18  
 primary immune deficiency-associated, 112
- Voriconazole, 239, 241–242
- Wasserman test, 35
- Whooping cough. *See* Pertussis
- Willis, Thomas, 202
- Wiskott-Aldrich syndrome, 111, 112, 113, 115, 116
- X-linked lymphoproliferative disease, 112
- Yersinia enterocolitica*, superantigens of, 191
- Zidovudine, 142–143, 149  
 administration during labor and delivery, 150, 151, 152  
 neonatal administration of, 152
- Zithromax, 216